Kennametal Inc. (KMT) is well-poised for growth in the coming quarters, courtesy of the strong performance of its Infrastructure segment. The company's efforts to reward its shareholders handsomely add to its appeal.Based in Latrobe, PA, Kennametal is a manufacturer, marketer and distributor of high-speed metal cutting tools, tooling systems and wear-resistant parts. Its products are marketed through a number of channels to the end users, comprising manufacturers of machine tools, transportation vehicles an ...

Kennametal Inc. (KMT) is benefiting from the strong performance of the Infrastructure segment, driven by strength in the aerospace & defense and energy end markets arising from favorable order timing. The segment’s revenues increased 0.4% year over year in the first quarter of fiscal 2025 (ended September 2024). Despite the ongoing softness across the majority of end markets, the company is witnessing several positive trends in its key end markets that hold promise for its long-term growth. This includes an ...

Core Insights - The FDA has approved Revuforj® (revumenib) as the first menin inhibitor for treating relapsed or refractory acute leukemia with a KMT2A translocation in patients aged one year and older [1][2][3] - The approval is based on positive data from the AUGMENT-101 clinical trial, demonstrating a 21% complete remission rate among treated patients [2][3] - Syndax Pharmaceuticals is preparing to launch Revuforj and is committed to advancing its development for KMT2A-rearranged acute leukemias and mutant NPM1 AML [2][8] Efficacy and Safety - In the AUGMENT-101 trial, 104 patients were evaluated, with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 21% [2] - The median duration of CR+CRh was 6.4 months, and the median time to CR or CRh was 1.9 months [2] - The safety evaluation involved 135 patients, with common adverse reactions including hemorrhage (53%), nausea (51%), and infection (41%) [3][18] Market Availability - Revuforj tablets (110 mg and 160 mg) are expected to be available for order in the U.S. in November 2024, with 25 mg tablets anticipated in early 2025 [4] - An oral solution of revumenib will be available through an expanded access program for patients weighing less than 40 kg prior to the commercial availability of the 25 mg tablets [4] Company Commitment - Syndax has established SyndAccess™, a program providing personalized support and financial assistance to U.S. patients prescribed Revuforj [5] - The company is focused on removing barriers to access for patients and enhancing support resources [5] Future Developments - Revumenib is also in development for treating R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1), with ongoing trials in combination with standard-of-care agents [8][9] - The company is conducting multiple clinical trials across the treatment landscape for KMT2A-rearranged acute leukemia and mNPM1 AML [8][22]

PITTSBURGH, Nov. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is proud to announce that it has been recognized as one of Caterpillar Inc's top indirect suppliers in 2024. This prestigious recognition reflects Kennametal's continued dedication to delivering innovative solutions, productivity improvements and outstanding customer and applications engineering support. Key drivers of this recognition include Kennametal's exceptional support in the successful launch of the Cat C27B and C32 cylinder head ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

PITTSBURGH, Nov. 12, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the UBS Global Industrials and Transportation Conference in Manalapan, Florida.Details of the conference are as follows:             When:      Tuesday, December 3, 2024             Attendees: Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About KennametalWith over 85 years as an industrial technology leader, Kennametal In ...

Kennametal Inc. (KMT) reported first-quarter fiscal 2025 (ended Sept. 30, 2024) adjusted earnings of 29 cents per share, which beat the Zacks Consensus Estimate of 25 cents. The bottom line decreased 29.3% from the year-ago figure.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.KMT’s Revenue DetailsKennametal’s revenues were $481.9 million, which decreased 2% from the year-ago quarter’s figure. Organic sales declined 2% year over year. Business days had a positive impact of 1%. Curr ...

Kennametal Inc. (NYSE:KMT) Q1 2025 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Michael Pici - Vice President of Investor Relations Sanjay Chowbey - President and Chief Executive Officer Pat Watson - Vice President and Chief Financial Officer Conference Call Participants Steven Fisher - UBS Julian Mitchell - Barclays Steve Barger - KeyBanc Capital Markets Angel Castillo - Morgan Stanley Tami Zakaria - JPMorgan Chris Dankert - Loop Capital Markets Joe Ritchie - Goldman Sachs Oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number 1-5318 KENNAMETAL INC. (Exact name of registrant as specified in its charter) Pennsylvania 25-0900168 (S ...

Kennametal (KMT) reported $481.95 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 2.1%. EPS of $0.29 for the same period compares to $0.41 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $480.69 million, representing a surprise of +0.26%. The company delivered an EPS surprise of +16.00%, with the consensus EPS estimate being $0.25.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- a ...